Literature DB >> 12530936

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

Frank T Ruschitzka.   

Abstract

Entities:  

Year:  2003        PMID： 12530936     DOI： 10.1007/s11906-003-0011-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  4 in total

1.  Vasopeptidase inhibition and angio-oedema.

Authors:  F H Messerli; J Nussberger
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

2.  Angioedema due to ACE inhibitors: increased risk in patients of African origin.

Authors:  C R Gibbs; G Y Lip; D G Beevers
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

Review 3.  Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?

Authors:  R Corti; J C Burnett; J L Rouleau; F Ruschitzka; T F Lüscher
Journal:  Circulation       Date:  2001-10-09       Impact factor: 29.690

4.  Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

Authors:  J L Rouleau; M A Pfeffer; D J Stewart; D Isaac; F Sestier; E K Kerut; C B Porter; G Proulx; C Qian; A J Block
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.